Screener
Sionna Therapeutics SION Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Sionna Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Sionna Therapeutics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 7:17 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033876
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | $18,963 | $13,668 |
| General and administrative | 10,636 | 5,991 |
| Total operating expenses | 29,599 | 19,659 |
| Loss from operations | (29,599) | (19,659) |
| Other income: | ||
| Interest income | 2,820 | 3,000 |
| Other income | — | 177 |
Item 1. Financial Statements
FAQ
- What is Sionna Therapeutics's total operating expenses?
- Sionna Therapeutics (SION) reported total operating expenses of $29.6M in Q1 2026.
- How has Sionna Therapeutics's total operating expenses changed year-over-year?
- Sionna Therapeutics's total operating expenses increased by 50.6% year-over-year, from $19.66M to $29.6M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Sionna Therapeutics's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude